Definitive chemoradiotherapy of limited-disease small cell lung cancer: Retrospective analysis of new predictive factors affecting treatment results

Komatsu, Tetsuya; Oizumi, Yukio; Kunieda, Etsuo; Tamai, Yoshifumi; Akiba, Takeshi; Kogawa, Asuka

doi:10.3892/ol.2011.361

Cited by 5 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Murray et al . reported that the prolongation of SER (time between the start of any treatment and the end of radiation therapy) resulted in more frequent brain metastasis, and a study from Japan yielded similar results, causing the author to speculate that SER affects survival because of the probability of distant metastasis, but not local control . This tendency was also demonstrated in our study; specifically, the DM rates in the late TRT group were significantly higher than those in the early TRT group, and the LRR rates were not significantly different between the two groups.…”

Section: Discussionsupporting

confidence: 84%

“…Patients who received early TRT typically presented with good hematopoietic function and could tolerate concurrent chemoradiotherapy, and it is widely known that concurrent chemoradiotherapy is superior to a sequential regimen in the treatment of SCLC . More importantly, patients in the early TRT group had short durations between the start of chemotherapy and radiotherapy administration, which has been demonstrated to affect survival in several previous studies . Murray et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited‐stage small‐cell lung cancer?

et al. 2015

View full text Add to dashboard Cite

BackgroundTo investigate whether the response to induction chemotherapy (IC) would impact the timing of thoracic radiotherapy (TRT) in limited-stage small-cell lung cancer (LS-SCLC).MethodsA total of 146 patients with LS-SCLC who had received two to six cycles of IC followed by TRT from January 2009 to December 2011 at our hospital were included in this study. Patients were divided into two groups based on the time TRT was administered: early TRT (administered after 2–3 cycles of chemotherapy) or late TRT (administered after 4–6 cycles). Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method. Multivariate Cox regression analysis was performed to evaluate the independent factors affecting survival.ResultsThe median OS for patients who received early TRT and late TRT was 29.0 and 19.9 months, respectively, (P = 0.018) and the median PFS was 18.5 and 13.8 months, respectively (P = 0.049). In patients who achieved complete remission (CR) or partial remission (PR) after two to three cycles of IC, the median OS was 36.1 and 22.5 months in the early and late TRT subgroups, respectively (P = 0.009); the corresponding median PFS was 20.2 and 13.8 months, respectively (P = 0.038). In the patients who did not achieve CR or PR, no statistic difference was found in OS or PFS between the two subgroups.ConclusionPatients who received early TRT had more favorable outcomes than those who received late TRT. Patients who achieved CR or PR after two to three cycles of IC obtained more benefit from early TRT.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited‐stage small‐cell lung cancer?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Among the clinical factors that may affect limitedstage SCLC, the size of the tumor and local lymph node metastasis may be the most important prognostic factors. In 2007, the IASLC used the seventh edition of Lung Cancer TNM staging to evaluate SCLC's prognosis (7,8) retrospectively. A total of 12,620 cases were included, of which 8,088 were suitable for TNM staging.…”

Section: Discussionmentioning

confidence: 99%

A retrospective analysis of prognostic factors for 160 patients with stage III small cell lung cancer

Liu¹,

Xin²,

Zhu³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: In some patients with stage III small cell lung cancer (SCLC), it is found that the treatment mode of systemic chemotherapy followed by auxiliary radiotherapy is better than early radiotherapy, but there is no clear evidence-based medical explanation for this. This study was designed to retrospectively evaluate prognostic factors for patients with stage III SCLC and explore the best treatment mode for locally advanced SCLC.Methods: A total of 160 patients with stage III SCLC who underwent chemotherapy or chest radiotherapy were enrolled in this study, including 103 patients at stage IIIA and 57 patients at stage IIIB. The short-term and long-term outcomes following chemotherapy and chest radiotherapy were compared between the two groups.Results: There was no significant difference in progression-free survival (PFS) (9.5 vs. 10.0 months, P=0.065) or overall survival (OS) (14.0 vs. 14.0 months, P=0.231) between early radiotherapy and late radiotherapy in stage IIIA SCLC. PFS in stage IIIB patients was longer in the late radiotherapy group than in early radiotherapy (11.0 vs. 9.0 months, P=0.041), but the difference in OS was not statistically significant between the two groups (14.0 vs. 17.0 months, P=0.110). There was no significant difference in short-term and long-term therapeutic effects between stages IIIA and IIIB. Patients with stage IIIB who received late radiotherapy seemed to have a survival advantage, but the difference was not statistically significant (P=0.549).Conclusions: Treatment mode had no impact on patients at stage IIIA. Late radiotherapy showed more effectiveness for patients at stage IIIB.

show abstract

“…And they were further divided into early RT or late RT groups based on the time thoracic RT was initiated. Early RT included patients who received RT before the beginning of the 4 th cycle of chemotherapy and late RT included patients who received RT after the beginning of the 4 th cycle of chemotherapy ( 6 , 7 ).…”

Section: Methodsmentioning

confidence: 99%

One Cycle of Concurrent Chemotherapy vs. Two Cycles of Concurrent Chemotherapy With Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe optimal number of concurrent chemotherapy cycles during thoracic radiotherapy (RT) in patients with limited stage-small cell lung cancer (LS-SCLC) is not well defined. The purpose of this study was to evaluate the impact of the number of concurrent chemotherapy cycles on prognosis of LS-SCLC.Material and MethodsPatients with LS-SCLC treated with concurrent chemo-radiotherapy from May 2008 to December 2020 in our hospital were retrospectively analyzed. The prescribed radiation dose was 60Gy administrated with conventional RT in 30 fractions within 6 weeks. The prognostic role of cycle number of chemotherapy administrated concurrently with RT were analyzed. All patients were followed up at one month after the treatment, then once every three months until two years after the treatment, and every six months thereafter. Propensity score matching (PSM) was performed to reduce confounding factors. The primary endpoint was overall survival (OS). Survival analysis was performed with Kaplan-Meier and multivariate analysis was performed with Cox regression model.ResultsAmong the 370 patients who received radical radiotherapy, 206 patients received concurrent chemo-radiotherapy and were included for the analysis. Multivariate analysis showed that stage and PCI were independent prognostic factors for OS. The median OS in patients who received one cycle and two cycles of chemotherapy concurrently with RT were 32.9 months and 31.6 months, respectively (P = 0.241). And the median PFS were 20.6 months and 18.4 months, respectively (P = 0.764). After PSM, no statistical differences in OS and PFS were observed between patients who received one cycle and those who received two cycles of concurrent chemotherapy.ConclusionTwo cycles of concurrent chemotherapy during RT were not necessarily superior compared to one cycle in LS-SCLC. The optimal cycle number of concurrent chemotherapy during RT needs to be further studied.

show abstract

Definitive chemoradiotherapy of limited-disease small cell lung cancer: Retrospective analysis of new predictive factors affecting treatment results

Cited by 5 publications

References 26 publications

Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited‐stage small‐cell lung cancer?

Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited‐stage small‐cell lung cancer?

A retrospective analysis of prognostic factors for 160 patients with stage III small cell lung cancer

One Cycle of Concurrent Chemotherapy vs. Two Cycles of Concurrent Chemotherapy With Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer

Contact Info

Product

Resources

About